GeneProt Offers Proteins to Serono for Testing and Licensing

Last week, GeneProt of Geneva announced an agreement with Geneva-based biopharmaceutical firm Serono that might lead to a licensing deal for GeneProt’s proteins.

Under the agreement, which will initially last for one year, Serono will receive a set of less than 50 synthesized polypeptides and proteins from GeneProt to test using its screening platform. The company then has an option to license the proteins exclusively.